{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:32:43Z","timestamp":1761561163578,"version":"3.40.5"},"reference-count":39,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,6,1]]},"abstract":"<jats:p>BACKGROUND. The benefits of exogenous surfactants for prevention or treatment of respiratory distress syndrome are well established, but there is a paucity of long-term follow-up data from surfactant-comparison trials.<\/jats:p>\n               <jats:p>OBJECTIVE. We sought to determine and compare survival and pulmonary and neurodevelopmental outcomes through 1 year corrected age of preterm infants who received lucinactant and other surfactants in the SELECT (Safety and Effectiveness of Lucinactant Versus Exosurf in a Clinical Trial) and STAR (Surfaxin Therapy Against Respiratory Distress Syndrome) trials individually and, secondarily, from analysis using combined data from these 2 trials.<\/jats:p>\n               <jats:p>METHODS. All infants from both trials who were randomly assigned to administration of lucinactant (175 mg\/kg), colfosceril palmitate (67.5 mg\/kg), beractant (100 mg\/kg), or poractant alfa (175 mg\/kg) were prospectively followed through 1 year corrected age, at which point masked assessment of outcomes was performed for surviving infants. One-year survival was a key outcome of interest. Other parameters assessed included rates of rehospitalization and respiratory morbidity and gross neurologic status. Data were analyzed by comparing the different surfactants within each trial and, in secondary analysis, combining data from both trials to compare lucinactant versus the animal-derived surfactants (beractant and poractant) used in these trials. Survival rates over time were compared by using the Wilcoxon test for survival through 1 year corrected age and logistic regression for comparison of fixed time points. The latter analyses were performed by using the prespecified approach, where loss to follow-up or withdrawal of consent was imputed as a death, and also using raw data. Other outcomes were analyzed by using the Cochran-Mantel-Haenszel test or logistic regression for categorical data, and analysis of variance on ranks was used for continuous data.<\/jats:p>\n               <jats:p>RESULTS. Very few cases were lost to follow-up in either trial (29 of 1546 enrolled in both trials [1.9%]). In the primary analysis of the SELECT trial comparing lucinactant to either colfosceril or beractant, there were no significant differences in the proportion of infants who were alive through 1 year corrected age. Fixed-time-point estimates of mortality at 1 year corrected age imputing loss to follow-up as a death were 28.1% for lucinactant, 31.0% for colfosceril, and 31.0% for beractant. By using raw data without imputing loss to follow-up as a death, mortality estimates at 1 year corrected age were computed to be 26.6%, 29.1%, and 28.3%, respectively. In the primary analysis of the STAR trial, significantly more infants treated with lucinactant were alive through 1 year corrected age compared with those who received poractant alfa. Fixed time estimates of mortality at 1 year corrected age imputing loss to follow-up as a death were 19.4% for lucinactant and 24.2% for poractant. These estimates using raw data that did not impute loss to follow-up as a death were 18.6% and 21.9%, respectively. In the combined analysis, survival through 1 year corrected age was higher for infants in the lucinactant group versus that of the infants in the animal-derived surfactants (beractant and poractant) group. The fixed-time-point estimates of mortality at 1 year corrected age imputing loss to follow-up as a death for lucinactant and animal-derived surfactants were 26.0% and 29.4%, respectively. However, the 1-year-corrected-age estimates using combined raw data were 24.6% for the lucinactant group and 26.7% for the animal-derived surfactant group. The incidence of postdischarge rehospitalizations, total number of rehospitalizations, incidence of respiratory illnesses, and total number of respiratory illnesses were generally similar among those in the treatment groups. Neurologic status at 1 year corrected age was essentially similar between infants who received lucinactant and those who received all other surfactants used in these 2 trials.<\/jats:p>\n               <jats:p>CONCLUSIONS. Findings from this 1-year follow-up of both lucinactant trials indicate that this new peptide-based synthetic surfactant is at least as good, if not superior, to animal-derived surfactants for prevention of respiratory distress syndrome and may be a viable alternative to animal-derived products.<\/jats:p>","DOI":"10.1542\/peds.2006-0149","type":"journal-article","created":{"date-parts":[[2007,5,29]],"date-time":"2007-05-29T00:25:35Z","timestamp":1180398335000},"page":"e1361-e1370","source":"Crossref","is-referenced-by-count":50,"title":["One-Year Follow-up of Very Preterm Infants Who Received Lucinactant for Prevention of Respiratory Distress Syndrome: Results From 2 Multicenter Randomized, Controlled Trials"],"prefix":"10.1542","volume":"119","author":[{"given":"Fernando","family":"Moya","sequence":"first","affiliation":[{"name":"Department of Neonatology, Coastal Area Health Education Center, Wilmington, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Sinha","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, James Cook University Hospital, Middlesbrough, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz","family":"Gadzinowski","sequence":"additional","affiliation":[{"name":"Department of Neonatology, University of Medical Sciences, Poznan, Poland"},{"name":"Department of Neonatology, Mother's Memorial Hospital Research Institute, Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"D'Agostino","sequence":"additional","affiliation":[{"name":"Department of Mathematics, Boston University, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Segal","sequence":"additional","affiliation":[{"name":"Medical Affairs, Discovery Laboratories, Inc, Warrington, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Guardia","sequence":"additional","affiliation":[{"name":"Medical Affairs, Discovery Laboratories, Inc, Warrington, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Mazela","sequence":"additional","affiliation":[{"name":"Department of Neonatology, University of Medical Sciences, Poznan, Poland"},{"name":"Medical Affairs, Discovery Laboratories, Inc, Warrington, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genzhou","family":"Liu","sequence":"additional","affiliation":[{"name":"Medical Affairs, Discovery Laboratories, Inc, Warrington, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the SELECT and STAR Study Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2007,6,1]]},"reference":[{"doi-asserted-by":"crossref","unstructured":"Soll RF, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev.\u20082001;(2):CD000144","key":"2021120902015981200_R1","DOI":"10.1002\/14651858.CD000144"},{"doi-asserted-by":"crossref","unstructured":"Notter RH, Wang Z, Egan EA, Holm BA. Component-specific surface and physiological activity in bovine-derived lung surfactants. Chem Phys Lipids.\u20082002;114:21\u201334","key":"2021120902015981200_R2","DOI":"10.1016\/S0009-3084(01)00197-9"},{"doi-asserted-by":"crossref","unstructured":"Curstedt T, Jo\u0308rnvall H, Robertson B, Bergman T, Berggren P. Two hydrophobic low-molecular-mass protein fractions of pulmonary surfactant: characterization and biophysical activity. Eur J Biochem.\u20081987;168:255\u2013262","key":"2021120902015981200_R3","DOI":"10.1111\/j.1432-1033.1987.tb13414.x"},{"doi-asserted-by":"crossref","unstructured":"Clark JC, Wert SE, Bachurski CJ, et al. Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice. Proc Natl Acad Sci USA.\u20081995;92:7794\u20137798","key":"2021120902015981200_R4","DOI":"10.1073\/pnas.92.17.7794"},{"doi-asserted-by":"crossref","unstructured":"Nogee LM, Garnier G, Dietz HC, et al. A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J Clin Invest.\u20081994;93:1860\u20131863","key":"2021120902015981200_R5","DOI":"10.1172\/JCI117173"},{"doi-asserted-by":"crossref","unstructured":"Nogee LM, Dunbar AE III, Wert SE, Askin F, Hamvas A, Whitsett JA. Brief report: a mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med.\u20082001;344:573\u2013579","key":"2021120902015981200_R6","DOI":"10.1056\/NEJM200102223440805"},{"doi-asserted-by":"crossref","unstructured":"Cochrane CG, Revak SD. Pulmonary surfactant protein B (SP-B): structure-function relationships. Science.\u20081991;254:566\u2013568","key":"2021120902015981200_R7","DOI":"10.1126\/science.1948032"},{"doi-asserted-by":"crossref","unstructured":"Andersson S, Kheiter A, Merritt TA. Oxidative inactivation of surfactants. Lung.\u20081999;177:179\u2013189","key":"2021120902015981200_R8","DOI":"10.1007\/PL00007639"},{"doi-asserted-by":"crossref","unstructured":"Revak SD, Merritt TA, Cochrane CG, et al. Efficacy of synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys. Pediatr Res.\u20081996;39:715\u2013724","key":"2021120902015981200_R9","DOI":"10.1203\/00006450-199604000-00025"},{"doi-asserted-by":"crossref","unstructured":"Cochrane CG, Revak SD, Merritt TA, et al. The efficacy and safety of KL4-surfactant in preterm infants with respiratory distress syndrome. Am J Respir Crit Care Med.\u20081996;153:404\u2013410","key":"2021120902015981200_R10","DOI":"10.1164\/ajrccm.153.1.8542150"},{"doi-asserted-by":"crossref","unstructured":"Moya FR, Gadzinowski J, Bancalari E, et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics.\u20082005;115:1018\u20131029","key":"2021120902015981200_R11","DOI":"10.1542\/peds.2004-2183"},{"doi-asserted-by":"crossref","unstructured":"Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, et al. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very preterm infants at high risk for respiratory distress syndrome. Pediatrics.\u20082005;115:1030\u20131038","key":"2021120902015981200_R12","DOI":"10.1542\/peds.2004-2231"},{"doi-asserted-by":"crossref","unstructured":"D'Agostino RB Sr, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues\u2014the encounters of academic consultants in statistics. Stat Med.\u20082003;22:169\u2013186","key":"2021120902015981200_R13","DOI":"10.1002\/sim.1425"},{"unstructured":"International conference on harmonisation; guidance on statistical principles for clinical trials: availability\u2014FDA. Notice. Fed Regist.\u20081998:63:49583\u201349598","key":"2021120902015981200_R14"},{"doi-asserted-by":"crossref","unstructured":"Cupples LA, Gagnon DR, Ramaswamy R, D'Agostino RB. Age-adjusted survival curves with application in the Framingham study. Stat Med.\u20081995;14:1731\u20131744","key":"2021120902015981200_R15","DOI":"10.1002\/sim.4780141603"},{"doi-asserted-by":"crossref","unstructured":"Soll RF. Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev.\u20081997;(4):CD000511","key":"2021120902015981200_R16","DOI":"10.1002\/14651858.CD000511"},{"unstructured":"Soll RF. Synthetic surfactant for respiratory distress syndrome in preterm infants [Cochrane review]. In: The Cochrane Library. Issue 2. Chichester, United Kingdom: John Wiley & Sons, Ltd; 2004","key":"2021120902015981200_R17"},{"doi-asserted-by":"crossref","unstructured":"Horbar JD, Wright LL, Soll RF, et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. J Pediatr.\u20081993;123:757\u2013766","key":"2021120902015981200_R18","DOI":"10.1016\/S0022-3476(05)80856-X"},{"unstructured":"Vermont-Oxford Network. A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Pediatrics.\u20081996;97:1\u20136","key":"2021120902015981200_R19"},{"unstructured":"Alvarado M, Hingre R, Hakason D, Gross S. Clinical trial of Survanta versus Exosurf in infants &lt;1500 g with respiratory distress syndrome [abstract]. Pediatr Res.\u20081993;33:314A","key":"2021120902015981200_R20"},{"doi-asserted-by":"crossref","unstructured":"da Costa DE, Pai MG, Al Khusaiby SM. Comparative trial of artificial and natural surfactants in the treatment of respiratory distress syndrome of prematurity: experiences in a developing country. Pediatr Pulmonol.\u20081999;27:312\u2013317","key":"2021120902015981200_R21","DOI":"10.1002\/(SICI)1099-0496(199905)27:5<312::AID-PPUL3>3.0.CO;2-N"},{"unstructured":"Modanlou HD, Beharry K, Padilla G, Norris K, Safvati S, Aranda JV. Comparative efficacy of Exosurf and Survanta surfactants on early clinical course of respiratory distress syndrome and complications of prematurity. J Perinatol.\u20081997;17:455\u2013460","key":"2021120902015981200_R22"},{"unstructured":"Pearlman SA, Leef KH, Stefano JL, et al. A randomized trial comparing Exosurf versus Survanta in the treatment of neonatal RDS [abstract]. Pediatr Res.\u20081993;33:340A","key":"2021120902015981200_R23"},{"unstructured":"Sehgal SS, Ewing CK, Richards T, Taeusch HW. Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study. J Natl Med Assoc.\u20081994;86:46\u201352","key":"2021120902015981200_R24"},{"doi-asserted-by":"crossref","unstructured":"Hudak ML, Farrell EE, Rosenberg AA, et al. A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. J Pediatr.\u20081996;128:396\u2013406","key":"2021120902015981200_R25","DOI":"10.1016\/S0022-3476(96)70291-3"},{"doi-asserted-by":"crossref","unstructured":"Hudak ML, Martin DJ, Egan EA, et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics.\u20081997;100:39\u201350","key":"2021120902015981200_R26","DOI":"10.1542\/peds.100.1.39"},{"doi-asserted-by":"crossref","unstructured":"Kukkonen AK, Virtanen M, Ja\u0308rvenpa\u0308a\u0308 AL, Pokela ML, Ikonen S, Fellman V. Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant?Acta Paediatr.\u20082000;89:556\u2013561","key":"2021120902015981200_R27","DOI":"10.1111\/j.1651-2227.2000.tb00338.x"},{"doi-asserted-by":"crossref","unstructured":"Ainsworth SB, Beresford MW, Milligan DWA, et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25\u201329 weeks' gestation: a randomised trial [published correction appears in Lancet. 2000;356:600]. Lancet.\u20082000;355:1387\u20131392","key":"2021120902015981200_R28","DOI":"10.1016\/S0140-6736(00)02136-X"},{"doi-asserted-by":"crossref","unstructured":"Horbar JD, Badger GJ, Carpenter JH, et al. Trends in mortality and morbidity for very low birth weight infants, 1991\u20131999. Pediatrics.\u20082002;110:143\u2013151","key":"2021120902015981200_R29","DOI":"10.1542\/peds.110.1.143"},{"doi-asserted-by":"crossref","unstructured":"Bloom BT, Kattwinkel J, Hall RT, et al. Comparison of Infasurf (calf lung surfactant extract) to Survanta (beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics.\u20081997;100:31\u201338","key":"2021120902015981200_R30","DOI":"10.1542\/peds.100.1.31"},{"doi-asserted-by":"crossref","unstructured":"Bloom BT, Clark RH; Infasurf Survanta Clinical Trial Group. Comparison of Infasurf (calfactant) and Survanta (beractant) in the prevention and treatment of respiratory distress syndrome. Pediatrics.\u20082005;116:392\u2013399","key":"2021120902015981200_R31","DOI":"10.1542\/peds.2004-2783"},{"doi-asserted-by":"crossref","unstructured":"Speer CP, Gefeller O, Groneck P, et al. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed.\u20081995;72:F8\u2013F13","key":"2021120902015981200_R32","DOI":"10.1136\/fn.72.1.F8"},{"doi-asserted-by":"crossref","unstructured":"Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K; North American Study Group. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol.\u20082004;21:109\u2013119","key":"2021120902015981200_R33","DOI":"10.1055\/s-2004-823779"},{"doi-asserted-by":"crossref","unstructured":"Malloy CA, Nicoski P, Muraskas JK. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatr.\u20082005;94:779\u2013784","key":"2021120902015981200_R34","DOI":"10.1111\/j.1651-2227.2005.tb01984.x"},{"doi-asserted-by":"crossref","unstructured":"Halliday HL. History of surfactant from 1980. Biol Neonate.\u20082005;87:317\u2013322","key":"2021120902015981200_R35","DOI":"10.1159\/000084879"},{"doi-asserted-by":"crossref","unstructured":"Sinn JK, Ward MC, Henderson-Smart DJ. Developmental outcome of preterm infants after surfactant therapy: systematic review of randomized controlled trials. J Paediatr Child Health.\u20082002;38:597\u2013600","key":"2021120902015981200_R36","DOI":"10.1046\/j.1440-1754.2002.00061.x"},{"doi-asserted-by":"crossref","unstructured":"Sell M, Cotton R, Hirata T, et al. One-year follow-up of 273 infants with birth weights of 700 to 1100 grams after prophylactic treatment of respiratory distress syndrome with synthetic surfactant or air placebo. American Exosurf Neonatal Study Group I. J Pediatr.\u20081995;126(5 pt 2):S20\u2013S25","key":"2021120902015981200_R37","DOI":"10.1016\/S0022-3476(95)70004-8"},{"doi-asserted-by":"crossref","unstructured":"Survanta Multidose Study Group. Two-year follow-up of infants treated for neonatal respiratory distress syndrome with bovine surfactant. J Pediatr.\u20081994;124:962\u2013967","key":"2021120902015981200_R38","DOI":"10.1016\/S0022-3476(05)83193-2"},{"doi-asserted-by":"crossref","unstructured":"Robertson B, Curstedt T, Tubman R, et al. A 2-year follow up of babies enrolled in a European multicentre trial of porcine surfactant replacement for severe neonatal respiratory distress syndrome. Collaborative European Multicentre Study Group. Eur J Pediatr.\u20081992;151:372\u2013376","key":"2021120902015981200_R39","DOI":"10.1007\/BF02113261"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/119\/6\/e1361\/1119930\/zpe006070e1361.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/119\/6\/e1361\/1119930\/zpe006070e1361.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T08:51:54Z","timestamp":1639039914000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/119\/6\/e1361\/70619\/One-Year-Follow-up-of-Very-Preterm-Infants-Who"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,1]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2007,6,1]]},"published-print":{"date-parts":[[2007,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2006-0149","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"subject":[],"published":{"date-parts":[[2007,6,1]]}}}